At Neuroendocrine Cancer UK, we have been actively collaborating with our charity partners to tackle the urgent need to resolve the ongoing shortages of Pancreatic Enzyme Replacement Therapy (PERT). Our joint efforts have resulted in significant strides towards ensuring a more stable supply for those who depend on this vital medication.
In this update, we outline the latest developments, including important alerts sent across NHS organisations, advice on approved unlicensed products, and the publication of an updated Position Statement by the Pancreatic Society of Great Britain & Ireland (PSGBI).
We encourage everyone affected by PERT shortages to review this document and share it with your healthcare providers. Additionally, we thank those who have participated in our PERT survey and continue to invite more responses to help us advocate for better solutions.
For the latest clinician and patient information, visit www.psgbi.org/position-statement-pert-shortage/
If you are experiencing any difficulties with your PERT prescription, please download and print the provided document to share with your prescribing and/or dispensing teams.
As we continue to work with our community, charity colleagues, and other stakeholders, including the DHSC and NHS, we aim to achieve a sustainable solution. In the meantime, if you or a loved one needs support and/or information, please reach out to our helpline support team.
For full details, please read the document below.
